Opinion

Video

Metastatic Prostate Cancer Treatment Approach

Author(s):

Matthew Smith, MD, PhD,Brian Helfand, MD, PhD

Focusing on metastatic prostate cancer, 2 experts have a comprehensive discussion on treatment options for patients with metastatic prostate cancer.

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
1 expert in this video
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Related Content
SBRT may offer a safe alternative to CFRT after prostatectomy
May 16th 2025

SBRT may offer a safe alternative to CFRT after prostatectomy

Hannah Clarke
Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr_Microbe - stock.adobe.come
May 13th 2025

MRI and focal therapy may enable men on AS to safely delay surgery or radiation

Hannah Clarke
Use of focal therapy was shown to prolong the duration of active surveillance.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com
May 2nd 2025

Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

Hannah Clarke
The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor
The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
© 2025 MJH Life Sciences

All rights reserved.